Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Chinese Journal of Biochemical Pharmaceutics ; (6): 46-48, 2015.
Article Dans Chinois | WPRIM | ID: wpr-484192

Résumé

Objective To explore the effect of gemcitabine combined with cisplatin on ER , MMP-9 and estrogen in patients with stage III breast cancer.Methods 93 patients with breast cancer were collected and randomly divided into control group and experimental group.Two groups were all under breast cancer surgery, control group was treated with cisplatin chemotherapy,1st day of intravenous infusion of cisplatin 90 mg/m2 , 21 days for a course of treatment, continuous treatment of 6 courses.Experimental group were treated with cisplatin combined with gemcitabine chemotherapy , 1st and 8th days of intravenous infusion of 1000 mg/m2 gemcitabine, 3 ~5d, intravenous drip of cisplatin 90 mg/m2 , every 28 days a cycle, continuous administration of 2 cycles,After treatment, the clinical efficacy of the two groups, the level of ER, MMP-9, estrogen and the incidence of adverse reactions were compared.Results Compared with before treatment,the levels of serum MMP-9,E1, E2, ER were decreased (P<0.05), and the level of LH and FSH were increased (P<0.05) of two group post-treatment.Compared with control group post-treatment, the levels of serum ER, MMP-9, E1, E2 were lower in experimental group (P<0.05), and the LH and FSH levels were higher (P <0.05).The incidence of adverse reactions of experimental group was 6.38%, and control group was 15.22%, the incidence of adverse reactions in the two groups was no significant difference . Conclusion Gemcitabine combined with cisplatin in the treatment of patients with breast cancer has a significant effect, and can improve the clinical symptoms, reduce the serum ER, E1, MMP-9, E2 levels, improve FSH, LH level.

SÉLECTION CITATIONS
Détails de la recherche